Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients
NCT02231580
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
17
Enrollment
INDUSTRY
Sponsor class
Stopped
The study was terminated due to subject recruitment problems.
Conditions
Huntington's Disease
Interventions
DRUG:
BN82451B
DRUG:
Placebo
Sponsor
Ipsen